Top ▲

protein kinase, DNA-activated, catalytic subunit

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 2800

Nomenclature: protein kinase, DNA-activated, catalytic subunit

Family: Other PIKK family kinases

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 4128 8q11.21 PRKDC protein kinase, DNA-activated, catalytic subunit
Mouse - 4128 16 A2 Prkdc protein kinase, DNA activated, catalytic polypeptide
Rat - - 11q23 Prkdc protein kinase, DNA-activated, catalytic subunit
Gene and Protein Information Comments
Isoform 1 of the human protein is the 4128 amino acid form in the table above. A second isoform, isoform 2 (NP_001075109), has also been reported and this has 4097 amino acids.
Previous and Unofficial Names Click here for help
DNA-dependent protein kinase catalytic subunit | protein kinase | protein kinase, DNA activated, catalytic polypeptide | protein kinase, DNA-activated, catalytic polypeptide | DNA-PK
Database Links Click here for help
Alphafold
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 82 [PMID: 21332118] Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.5 pKi 5
pKi 8.5 (Ki 3x10-9 M) [5]
wortmannin Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.9 pKi 6
pKi 6.9 (Ki 1.2x10-7 M) [6]
torin 2 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 9.3 pIC50 13
pIC50 9.3 (IC50 5x10-10 M) [13]
PIK-75 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.7 pIC50 11
pIC50 8.7 (IC50 2x10-9 M) [11]
peposertib Small molecule or natural product Primary target of this compound Ligand has a PDB structure Hs Inhibition >8.5 pIC50 8
pIC50 >8.5 (IC50 <3x10-9 M) [8]
KU-0060648 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.3 pIC50 4
pIC50 8.3 (IC50 5x10-9 M) [4]
AZD7648 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.0 – 9.2 pIC50 9
pIC50 9.2 (IC50 6.3x10-10 M) [9]
Description: Measured by time-resolved fluorescence (TR-FRET) in a biochemical assay.
pIC50 7.0 (IC50 9.1x10-8 M) [9]
Description: Measuring inhibition of irradiation-induced DNA-PK autophosphorylation in A549 cells by ELISA.
NU-7441 Small molecule or natural product Primary target of this compound Ligand has a PDB structure Hs Inhibition 7.8 pIC50 12
pIC50 7.8 (IC50 1.4x10-8 M) [12]
Description: ELISA measuring the ability of DNA-PK (extracted from HeLa cells) to phosphorylate Ser15 of a p53 peptide
PI-103 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.6 pIC50 14
pIC50 7.6 (IC50 2.3x10-8 M) [14]
PP121 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.2 pIC50 1
pIC50 7.2 (IC50 6x10-8 M) [1]
BAY-8400 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.1 pIC50 3
pIC50 7.1 (IC50 8.1x10-8 M) [3]
DNA-PK inhibitor III Small molecule or natural product Primary target of this compound Mm Inhibition 6.9 pIC50 6
pIC50 6.9 (IC50 1.2x10-7 M) [6]
Description: Inhibition of PRKDC in C57BL6 mouse endothelial cells
NU-7026 Small molecule or natural product Primary target of this compound Hs Inhibition 6.6 pIC50 10
pIC50 6.6 (IC50 2.3x10-7 M) [10]
DNA-PK inhibitor V Small molecule or natural product Primary target of this compound Hs Inhibition 6.6 pIC50 2
pIC50 6.6 (IC50 2.7x10-7 M) [2]
lartesertib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.2 pIC50 7
pIC50 6.2 (IC50 6x10-7 M) [7]
View species-specific inhibitor tables
Immunopharmacology Comments
Protein kinase, DNA-activated, catalytic polypeptide (DNA-PKcs) principally acts to repair DNA in a process called non-homologous end joining (NHEJ). NHEJ is required for V(D)J recombination (somatic recombination) in developing lymphocytes during the early stages of T and B cell maturation. DNA-PKcs knockout mice develop severe combined immunodeficiency as NHEJ is compromised and they are unable to construct the huge repertoire of antibodies and T cell receptors necessary for a fully developed adaptive immune response.
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Cytokine production & signalling
Immuno Process:  Cellular signalling
Immuno Process:  T cell (activation)
Immuno Process:  B cell (activation)
Immuno Process:  Immune regulation
Immuno Process:  Immune system development
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Immunodeficiency 26 with or without neurologic abnormalities; IMD26
Synonyms: Severe combined immunodeficiency due to DNA-PKcs deficiency [Orphanet: ORPHA317425]
OMIM: 615966
Orphanet: ORPHA317425

References

Show »

1. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol, 4 (11): 691-9. [PMID:18849971]

2. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ. (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. J Biol Chem, 282 (33): 24463-70. [PMID:17562705]

3. Berger M, Wortmann L, Buchgraber P, Lücking U, Zitzmann-Kolbe S, Wengner AM, Bader B, Bömer U, Briem H, Eis K et al.. (2021) BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. J Med Chem, 64 (17): 12723-12737. [PMID:34428039]

4. Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA et al.. (2013) 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem, 56 (16): 6386-401. [PMID:23855836]

5. D'Angelo ND, Kim TS, Andrews K, Booker SK, Caenepeel S, Chen K, D'Amico D, Freeman D, Jiang J, Liu L et al.. (2011) Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. J Med Chem, 54 (6): 1789-811. [PMID:21332118]

6. Finlay MR, Griffin RJ. (2012) Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett, 22 (17): 5352-9. [PMID:22835870]

7. Fuchas T, Becker A, Kubas H, Graedler U. (2020) Imidazolonylquinoline compounds and therapeutic uses thereof. Patent number: WO2020193660A1. Assignee: Merck Patent Gmbh. Priority date: 25/03/2020. Publication date: 01/10/2020.

8. Fuchss T, Ulrich E, Buchstakker H-P, Werner M. (2016) Arylquinazolines. Patent number: WO2014183850. Assignee: Merck Patent Gmbh. Priority date: 11/05/2013. Publication date: 24/03/2016.

9. Goldberg FW, Finlay MRV, Ting AKT, Beattie D, Lamont GM, Fallan C, Wrigley GL, Schimpl M, Howard MR, Williamson B et al.. (2020) The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. J Med Chem, 63 (7): 3461-3471. [PMID:31851518]

10. Hollick JJ, Golding BT, Hardcastle IR, Martin N, Richardson C, Rigoreau LJ, Smith GC, Griffin RJ. (2003) 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK). Bioorg Med Chem Lett, 13 (18): 3083-6. [PMID:12941339]

11. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B et al.. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell, 125 (4): 733-47. [PMID:16647110]

12. Leahy JJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L, Smith GC. (2004) Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett, 14 (24): 6083-7. [PMID:15546735]

13. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS. (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem, 54 (5): 1473-80. [PMID:21322566]

14. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F et al.. (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther, 8 (7): 1725-38. [PMID:19584227]

How to cite this page

Other PIKK family kinases: protein kinase, DNA-activated, catalytic subunit. Last modified on 09/01/2023. Accessed on 17/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2800.